

FLUOROTECHNOLOGY FOR HEALTHCARE APPLICATIONS

FluoroTechnology products are used throughout hospitals and healthcare settings. Fluoropolymers provide low-friction and clot-resistant coatings for catheters, stents and needles, improving patient comfort and safety, including in deep needle operations such as drug injections and biopsies. Fluoropolymers also allow for protein-resistant and sterile filters, tubing, o-rings, seals and gaskets for kidney dialysis machines and immuno-diagnostic instruments.



Fluoropolymers serve as high dielectric insulators that are critical to the proper function of electronics that rely on high frequency signals such as defibrillators, pacemakers and CRT, PET and MRI imaging devices.

Fluoropolymers provide a high barrier against humidity in blister packaging for sensitive pharmaceuticals, extending the shelf-life for dry formulations like pills and powders.

In hospital gowns, drapes and divider curtains, certain fluorinated polymers create a barrier that provides life-saving protection against infections and transmission of diseases in hospitals. Wall and floor paints employing FluoroTechnology allow for the aggressive use of biocides for cleaning, helping to prevent infections in hospitals.

The use of FluoroTechnology in the healthcare industry supports more than 1,000 jobs in both the U.S. and Europe. Globally, FluoroTechnology materials and products specific to the healthcare industry generate a total of \$965 million in economic output.¹

FluoroCouncil's Commitment to Sustainability

FluoroCouncil and its members are working with regulatory authorities and other stakeholders worldwide to innovate and drive increasingly sustainable FluoroTechnology solutions, including the global transition from long-chain PFAS² to alternatives such as short-chain fluorochemicals. Short-chain fluorochemicals are alternatives to the long-chain PFAS that provide the same valuable properties, but with improved environmental and human health profiles.

All FluoroCouncil companies are charter members of the [2010/2015 PFOA Stewardship Program](#), a global partnership with U.S. Environmental Protection Agency (EPA) based on goals to eliminate perfluorooctanoic acid (PFOA) and related chemicals from facility emissions and product content by the end of 2015. Similar programs are in place with Environment and Health Canada. A significant volume of data has been developed and rigorously evaluated by industry and regulators, supporting the conclusion that the short-chain alternative substances offer equivalent performance with improved environmental and human health profiles.

According to [the U.S. EPA](#), "data indicate that [shorter-chain chemicals] have substantially shorter half-lives in these animals than PFOA and are less toxic than long-chain PFAC chemicals."

¹ Based on preliminary estimates of 2013 data by the American Chemistry Council.

² PFAS = per- and polyfluoroalkyl substances

THE FLUOROCOUNCIL MEMBERS ARE:

Archroma Management LLC, Arkema France, Asahi Glass Co., Ltd., Daikin Industries, Ltd.,
Solvay Specialty Polymers, and The Chemours Company LLC